Juliane Hörner-Rieber1, Denise Bernhardt2, Julian Dern3, Laila König4, Sebastian Adeberg5, Angela Paul6, Claus Peter Heussel7, Jutta Kappes8, Hans Hoffmann9, Felix J P Herth10, Jürgen Debus11, Arne Warth12, Stefan Rieken13. 1. University Hospital Heidelberg, Department of Radiation Oncology, Heidelberg, Germany; National Center for Radiation Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Heidelberg, Germany. Electronic address: juliane.hoerner-rieber@med.uni-heidelberg.de. 2. University Hospital Heidelberg, Department of Radiation Oncology, Heidelberg, Germany; National Center for Radiation Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Heidelberg, Germany. Electronic address: julian.dern@med.uni-heidelberg.de. 3. University Hospital Heidelberg, Department of Radiation Oncology, Heidelberg, Germany; National Center for Radiation Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Heidelberg, Germany. Electronic address: denise.bernhardt@med.uni-heidelberg.de. 4. University Hospital Heidelberg, Department of Radiation Oncology, Heidelberg, Germany; National Center for Radiation Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Heidelberg, Germany. Electronic address: laila.koenig@med.uni-heidelberg.de. 5. University Hospital Heidelberg, Department of Radiation Oncology, Heidelberg, Germany; National Center for Radiation Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Heidelberg, Germany. Electronic address: sebastian.adeberg@med.uni-heidelberg.de. 6. University Hospital Heidelberg, Department of Radiation Oncology, Heidelberg, Germany; National Center for Radiation Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Heidelberg, Germany. Electronic address: angela.paul@med.uni-heidelberg.de. 7. Translational Research Unit, Thoraxklinik, Heidelberg University, Germany Translational Lung Research Centre Heidelberg (TLRC-H), Member of the German Centre for Lung Research (DZL), Heidelberg, Germany; Department of Diagnostic and Interventional Radiology, University-Hospital, Heidelberg, Germany; Department of Diagnostic and Interventional Radiology with Nuclear Medicine, Thoraxklinik at University-Hospital, Heidelberg, Germany. Electronic address: clauspeter.heussel@med.uni-heidelberg.de. 8. Translational Research Unit, Thoraxklinik, Heidelberg University, Germany Translational Lung Research Centre Heidelberg (TLRC-H), Member of the German Centre for Lung Research (DZL), Heidelberg, Germany; Department of Diagnostic and Interventional Radiology with Nuclear Medicine, Thoraxklinik at University-Hospital, Heidelberg, Germany. Electronic address: jutta.kappes@med.uni-heidelberg.de. 9. Translational Research Unit, Thoraxklinik, Heidelberg University, Germany Translational Lung Research Centre Heidelberg (TLRC-H), Member of the German Centre for Lung Research (DZL), Heidelberg, Germany; Department of Thoracic Surgery, Thoraxklinik, Heidelberg University, Heidelberg, Germany. Electronic address: hans.hoffmann@med.uni-heidelberg.de. 10. Translational Research Unit, Thoraxklinik, Heidelberg University, Germany Translational Lung Research Centre Heidelberg (TLRC-H), Member of the German Centre for Lung Research (DZL), Heidelberg, Germany; Department of Pneumology, Thoraxklinik, Heidelberg University, Heidelberg, Germany. Electronic address: felix.herth@med.uni-heidelberg.de. 11. University Hospital Heidelberg, Department of Radiation Oncology, Heidelberg, Germany; National Center for Radiation Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Heidelberg, Germany. Electronic address: juergen.debus@med.uni-heidelberg.de. 12. Department of Diagnostic and Interventional Radiology, University-Hospital, Heidelberg, Germany; Institute of Pathology, Heidelberg University, Heidelberg, Germany. Electronic address: arne.warth@med.uni-heidelberg.de. 13. University Hospital Heidelberg, Department of Radiation Oncology, Heidelberg, Germany; National Center for Radiation Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Heidelberg, Germany. Electronic address: stefan.rieken@med.uni-heidelberg.de.
Abstract
BACKGROUND AND PURPOSE: To investigate the prognostic impact of different histological subtypes of non-small cell lung cancer (NSCLC) on outcome following stereotactic body radiotherapy (SBRT) for NSCLC patients. MATERIALS AND METHODS: We analyzed 126 consecutive patients with early-stage adenocarcinoma or squamous cell carcinoma treated with SBRT from 2004 to 2016. Adenocarcinoma patients were further sub-classified as high-risk or low-risk tumors. RESULTS: With a median follow-up time of 22months, 2-year overall survival (OS), local (LC), and distant control (DC) were 68%, 90% and 79%, respectively. For LC, histologic subtype was identified as major independent prognostic factor (p=0.033): while LC was 81% for squamous cell carcinoma patients, LC was significantly improved for high-risk and even more non-high-risk adenocarcinoma patients with 96% and 100%, respectively (p=0.026). The negative prognostic impact of the histologic subtype "squamous cell carcinoma" was not evident when patients received SBRT with higher total doses in EQD2 (2Gy equivalent dose): if patients were treated with a total dose in EQD2≥150Gy, no significant difference in LC for histologic subtypes was detected anymore (p=0.355). CONCLUSION: In the current study, histologic subtypes of NSCLC predicted local control probabilities following SBRT. Prospective, multi-center studies are needed to evaluate the prognostic impact of histology and consecutively the need for SBRT dose adaptation.
BACKGROUND AND PURPOSE: To investigate the prognostic impact of different histological subtypes of non-small cell lung cancer (NSCLC) on outcome following stereotactic body radiotherapy (SBRT) for NSCLCpatients. MATERIALS AND METHODS: We analyzed 126 consecutive patients with early-stage adenocarcinoma or squamous cell carcinoma treated with SBRT from 2004 to 2016. Adenocarcinomapatients were further sub-classified as high-risk or low-risk tumors. RESULTS: With a median follow-up time of 22months, 2-year overall survival (OS), local (LC), and distant control (DC) were 68%, 90% and 79%, respectively. For LC, histologic subtype was identified as major independent prognostic factor (p=0.033): while LC was 81% for squamous cell carcinomapatients, LC was significantly improved for high-risk and even more non-high-risk adenocarcinomapatients with 96% and 100%, respectively (p=0.026). The negative prognostic impact of the histologic subtype "squamous cell carcinoma" was not evident when patients received SBRT with higher total doses in EQD2 (2Gy equivalent dose): if patients were treated with a total dose in EQD2≥150Gy, no significant difference in LC for histologic subtypes was detected anymore (p=0.355). CONCLUSION: In the current study, histologic subtypes of NSCLC predicted local control probabilities following SBRT. Prospective, multi-center studies are needed to evaluate the prognostic impact of histology and consecutively the need for SBRT dose adaptation.
Authors: Donata von Reibnitz; Fauzia Shaikh; Abraham J Wu; Gregory C Treharne; Rosalind Dick-Godfrey; Amanda Foster; Kaitlin M Woo; Weiji Shi; Zhigang Zhang; Shaun U Din; Daphna Y Gelblum; Ellen D Yorke; Kenneth E Rosenzweig; Andreas Rimner Journal: Acta Oncol Date: 2018-06-06 Impact factor: 4.089
Authors: Jingjing Kang; Matthew S Ning; Han Feng; Hongqi Li; Houda Bahig; Eric D Brooks; James W Welsh; Rui Ye; Hongyu Miao; Joe Y Chang Journal: Int J Radiat Oncol Biol Phys Date: 2019-10-03 Impact factor: 7.038
Authors: Nima Aghdam; Jonathan W Lischalk; Monica Pernia Marin; Clare Hall; Timothy O'Connor; Lloyd Campbell; Simeng Suy; Sean P Collins; Marc Margolis; Rebecca Krochmal; Eric Anderson; Brian T Collins Journal: Front Oncol Date: 2021-11-29 Impact factor: 6.244